Paolo Tarantino and Jason Mouabbi
Jun 8, 2025, 09:03
Jason Mouabbi and Paolo Tarantino Discuss How T-DXd + Pertuzumab Could Reshape Frontline Treatment in HER2+ mBC
Community Health Media shared a post on X:
“At ASCO25, first results from DESTINY-Breast09 (DB09) showed that T-DXd + pertuzumab outperformed standard THP in 1L HER2+ MBC.
Dr. Jason A. Mouabbi and Paolo Tarantino discuss how this regimen could reshape frontline treatment in HER2+ metastatic breast cancer.”
Paolo Tarantino, 2025 Yvonne ‘Top Voice’ Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared this post, adding:
“Months before the DB09 presentation, I had a fun discussion with Jason A. Mouabbi on how to implement the 1L T-DXd/P regimen in clinical practice.
All thought are still valid in this post-DB09 era. In which breast oncs will need, more than ever, to tailor, adapt, be artisans of oncology.”
Proceed to the video attached to the post.
More posts featuring Breast cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 08:43